About 300 reports

  • 2.4.3 LYSOSOMAL STORAGE DISEASE
  • GENETIC DISORDERS, AFFECTED AREAS OF LSDS

LSDs are a family of over ## diverse diseases related by their molecular pathology.

  • Neurological Disorder
  • World
  • Market Size
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • 5.3 MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES (DROC)

Over ## million American adults (## in ##) have at least one mental health condition.

  • Neurological Disorder
  • North America
  • United States
  • Market Size
  • Masimo Corporation
  • ELECTROENCEPHALOGRAPHY GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2015-2023) ($MN)

For single channel EEG recordings, three electrodes are needed one active, one reference and one ground. ##-channel device are implemented to perform tasks like EEG screening studies in case the neoplasm or cerebrovascular pathology, in suspected cerebral function

  • Neurological Disorder
  • World
  • Market Size
  • Compumedics Limited
  • Medtronic, Inc.

Laboratories performing genetic tests can be accredited through the Clinical Pathology Accreditation UK Ltd scheme.

  • Neurological Disorder
  • North America
  • United States
  • World
  • Forecast
  • MARKET CHALLENGES

AD is one of the most common types of NDDs.

  • Neurological Disorder
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • 12.1 BIBLIOGRAPHY

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE; ##(##): ##-##.

  • Neurological Disorder
  • United States
  • Forecast
  • Eisai Co., Ltd.
  • GW Pharmaceuticals plc

While the exact disease pathology is not fully understood, it is known that the symptoms largely result from reduced levels of a neurotransmitter called dopamine in the brain.

  • Neurological Disorder
  • World
  • Boston Scientific Corporation
  • Cyberonics, Inc.
  • Jude Medical, Inc.

The company focuses on developing novel therapies for urological pathologies with a focus on uro-oncology.

  • Neurological Disorder
  • Allergan plc
  • Galderma S.A.
  • Ipsen S.A.
  • Merz Pharmaceuticals GmbH
  • SOURCES

Gh. et al. (2013) ' Pathology of Multiple Sclerosis: Where Do We Stand? '

  • Neurological Disorder
  • Biogen Idec Inc.
  • Merck Serono S.A.
  • Novartis AG
  • Sanofi S.A.
  • 3.1 US Tardive Dyskinesia Market: An Analysis
  • US Tardive Dyskinesia Market by Number of Patients; 2016-2020 ('000)

However, due to unusual pathology related to tardive dyskinesia, the disease is underdiagnosed and represents a much larger population than is estimated.

  • Neurological Disorder
  • United States
  • Market Size
  • Teva Pharmaceutical Industries Ltd.
  • Valeant Pharmaceuticals International, Inc.

Also, one molecule with unknown status and one terminated molecule have been identified.

  • Neurological Disorder
  • Asterias Biotherapeutics, Inc.
  • Athersys, Inc.
  • Celgene Corporation
  • Enlivex
  • REFERENCES

Renal pathology in Fabry disease.

  • Mental Health
  • Neurological Disorder
  • Pathology

Scale = ##-##, where ## is low impact, and ## is high impact.

  • Neurological Disorder
  • World
  • Market Size
  • QIAGEN N.V.
  • Thermo Fisher Scientific, Inc.
  • INTRODUCTION

Genet Test. 2002; ##(##):##- ## ##.

  • Mental Health
  • Neurological Disorder
  • Pathology

Table ##.

  • Mental Health
  • Neurological Disorder
  • Pathology
  • Northern Europe
  • Western Europe
  • CAUSE OF THE DISEASE

EPILEPTIC SEIZURES ARE OBSERVED IN AUTOIMMUNE ENCEPHALOPATHIES INVOLVING AUTOANTIBODIES AND OTHER TYPES OF IMMUNE-RELATED PATHOLOGIES.

  • Neurological Disorder
  • Germany
  • Italy
  • Poland
  • Spain

Table ##.

  • Mental Health
  • Neurological Disorder
  • Pathology
  • Northern Europe
  • Western Europe
  • 5.1 BIBLIOGRAPHY

The American Journal of Pathology; ##(##): 2068-2076.

  • Neurological Disorder
  • Biogen Idec Inc.
  • Novartis AG
  • Roche Group
  • Sanofi S.A.
  • Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Therapeutics Clinical Trials Market,

(Inactive) ## ## ## ## ## Bluebird bio, Inc. ## ## ## ## ## Asklepion Pharmaceuticals, LLC ## ## ## ## ## NUVISAN GmbH ## ## ## ## ## Nutra Pharma Corporation ## ## ## ## ## Nuo Therapeutics, Inc. ## ## ## ## ## Neuralgene

  • Neurological Disorder
  • World
  • Aldagen, Inc.
  • Asklepion Pharmaceuticals, LLC
  • Nutra Pharma Corporation

Elekta achieved one milestone with zero helium boil-off technology.

  • Neurological Disorder
  • World
  • Covidien plc
  • Medtronic, Inc.
  • Nihon Kohden Corporation
  • 6.6 INCREASED KNOWLEDGE OF HD PATHOGENESIS
  • 3 Disease Overview

The American Journal of Pathology; ##(##): ##-##.

  • Neurological Disorder
  • United States
  • GlobalData's company
  • Huntington Study Group
  • Pfizer Inc.

Chapter ## ##-## Clinical Overview Chapter ## and intracranial hemorrhage is uncertain.

  • Neurological Disorder
  • United States
  • Forecast
  • GE Healthcare Limited
  • Stryker Corporation

It affects one in approximately ##, ## live births.

  • Neurological Disorder
  • Therapy
  • BioMarin Pharmaceutical
  • Lilly Endowment Inc.
  • PTC Therapeutics, Inc.
  • 3.4.1 SOURCES USED

Journal of Neurological Sciences; ##(##-##): ##-##.

  • Neurological Disorder
  • Japan
  • United States
  • World
  • Forecast

THE ALTERNATIVE COMPLEMENT PATHWAY MIGHT HAVE A ROLE IN MUSK MYASTHENIA, BUT OVERALL THE SIGNIFICANCE FOR PATHOLOGY REMAINS UNCERTAIN.

  • Neurological Disorder
  • Alexion Pharmaceuticals, Inc.
  • Astellas Pharma Inc.
  • GlobalData's company
  • Roche Group
  • MOLECULAR DIAGNOSTIC TEST - MULTIPLE SCLEROSIS - PRODUCT DESCRIPTION
  • MOLECULAR DIAGNOSTIC TEST - MULTIPLE SCLEROSIS - PRODUCT STATUS

It develops therapeutics for nervous system pathologies involving human endogenous retroviruses.

  • Autoimmune Disease
  • Clinical Trial
  • Neurological Disorder
  • United States
  • Grifols, S.A.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ## and ## respectively.

  • Neurological Disorder
  • United States
  • World
  • Product Initiative
  • Kadmon Corporation, LLC
  • parties expect the transaction to close mid-2016.
  • CSL LTD

It develops therapeutics for nervous system pathologies involving human endogenous retroviruses.

  • Neurological Disorder
  • Therapy
  • United States
  • World
  • Product Initiative

The molecules developed by Companies in Phase I, Preclinical and Discovery stages are ##, ## and ## respectively.

  • Neurological Disorder
  • Therapy
  • United States
  • World
  • AndroScience Corporation, Inc
  • Lysosomal Alpha Glucosidase (Acid Maltase or Aglucosidase Alfa or GAA or EC 3.2.1.20) - Product Development Milestones

This vector was confirmed to provide GAA expression and activity in target tissues, improved muscle pathology and a favorable immunogenicity profile.

  • Neurological Disorder
  • United States
  • World
  • Product Initiative
  • Amicus Therapeutics